ESR1 and breast carcinoma: For the everolimus–exemestane combination treatment in estrogen receptor–positive (ER+) breast cancer, the clinical benefit rate, defined as the proportion of patients with a complete response (CR), partial response (PR), or stable disease (SD) for at least 16 wk, was about 51%, and the overall response rate (CR + PR) was about 16% (Baselga et al., 2012).